ReviewmAbs
Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors.
Review in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Article
- From T cell engagers to next-generation immune cell engagers for cancer immunotherapy.Antibody therapeutics · 2026Review
- Engineering NKG2D ligand affinity transforms EGFR-targeted NK cell engagers into high-potency effectors against pancreatic cancer.Journal of biological engineering · 2026Article
- Advancing immunotherapy via multiple immune cells co-engagement.Frontiers in immunology · 2026Review
- NKG2D CAR-NK adoptive cellular immunotherapy combined with or without PD-1 blockade in the treatment of patients with metastatic colorectal cancer: an exploratory study.Cancer immunology, immunotherapy : CII · 2025Article
- CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity.Journal for immunotherapy of cancer · 2025Article
- 23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation.Cancer research communications · 2025Article
- Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer Treatment.Antibodies (Basel, Switzerland) · 2025Review
- γδT cells, a key subset of T cell for cancer immunotherapy.Frontiers in immunology · 2025Review
- Bispecific antibody for lung cancer: mechanisms and clinical insights.Frontiers in immunology · 2025Review
- NKG2D triggering hampers DNAM-1-mediated signaling in human NK cells.Frontiers in immunology · 2025Article
- Current Developments in NK Cell Engagers for Cancer Immunotherapy: Focus on CD16A and NKp46.Immune network · 2024Review
- Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy.Journal of translational medicine · 2024Review
- Review
- Article
- Soluble NKG2DLs Are Elevated in Breast Cancer Patients and Associate with Disease Outcome.International journal of molecular sciences · 2024Article
- The present and future of bispecific antibodies for cancer therapy.Nature reviews. Drug discovery · 2024Review
- Development of NK cell-based cancer immunotherapies through receptor engineering.Cellular & molecular immunology · 2024Review
- Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside.Cell death & disease · 2024Review
- Overcoming limitations for antibody-based therapies targeting γδ T (Vg9Vd2) cells.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The field of immuno-oncology has revolutionized cancer patient care and improved survival and quality of life for patients. Much of the focus in the field has been on exploiting the power of the adaptive immune response through therapeutic targeting of T cells. While these approaches have markedly advanced the field, some challenges remain, and the clinical benefit of T cell therapies does not extend to all patients or tumor indications. Alternative strategies, such as engaging the innate immune system, have become an intense area of focus in the field. In particular, the engagement of natural killer (NK) cells as potent effectors of the innate immune response has emerged as a promising modality in immunotherapy. Here, we review therapeutic approaches for selective engagement of NK cells for cancer therapy, with a particular focus on targeting the key activating receptors NK Group 2D (NKG2D) and cluster of differentiation 16A (CD16A).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.